Ca&Bone

[Hip fractures in Hungary between 2001 and 2008 - Assessment of the beneficial effect of bisphosphonates on the risk of hip fractures on the basis of Hungarian data]

HÉJJ Gábor

DECEMBER 28, 2009

Ca&Bone - 2009;12(03)

[The overall prevalence of osteoporosis in developed countries is estimated to be 9-15%. Mortality in the first year after the fracture is 15-20%, and half of the survivors remain partly or fully dependent on others’ support. Owing to the increasing life expectance and the diseases of civilisation, the incidence of osteoporotic fractures is expected to double in the next thirty years. The network of centers that has been developed since 1995 under the National Osteoporosis Program and the accreditation system of the National Osteoporosis Center provided up-to-date education of the physicians (densitometry assistants) who work within the network. The diagnostic restrictions followed by the reduction of support to 70% since 2006 fall resulted in a dramatic reduction in the number of treated patients.]

COMMENTS

0 comments

Further articles in this publication

Ca&Bone

[The risk factors of osteoporosis and osteoporotic fractures in Hungarian women: the results of the NOKK study]

MEZŐ Tibor, TABÁK Ádám, BHATTOA Harjit Pál, LAKATOS Péter

[INTRODUCTION - It is widely accepted from Western European and the US studies that race and geography significantly affect the risk for osteoporosis. Less is known about similar associations in Eastern European subjects. Our aim was to describe the risk factors for osteoporotic fractures and osteoporosis in a selected female population in a cross-sectional, multi-center study performed under the guidance of the Hungarian Society for osteoporosis and Osteoarthrology. MATERIAL AND METHOD - From 10 randomly selected regional osteoporosis centers, altogether 2602 women >18 years of age, referred with any osteoarthrological reason, participated. During their visit data on risk factors, blood pressure, anthropometry, and bone mineral density were collected. RESULTS - Using multiple regression we found that older age, lower diastolic blood pressure, family history of bone fracture, fall in previous year and lower T-score were independently related to fractures. Independent risk factors for femoral osteoporosis included older age, lower weight, family history of fracture, less physical activity, fall in the previous year and glucocorticoid treatment. DISCUSSION - Our study is the first large-scale epidemiological survey describing risk factors of osteoporosis and fractures in a Hungarian female population. Our data may suggest that lower diastolic blood pressure might be related to osteoporotic fractures.]

Ca&Bone

[Dear Readers! Dear Colleagues!]

HORVÁTH CSABA

Ca&Bone

[Vitamin D in autoimmun disorders: the immunregulatory effect of vitamin D and therapeutic opportunities]

ZÖLD Éva, SZODORAY Péter, GAÁL János, SZEGEDI Andrea, SZEGEDI Gyula, BODOLAY Edit

[There is recent evidence that genetic and environmental factors play an important role in the development of autoimmune diseases. Vitamin D deficiency is one of the environmental factors that may play a role in developing autoimmune diseases. Low vitamin D status has been implicated in the etiology of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, inzulin dependent diabetes mellitus, and inflammatory bowel disease. Experimentally, vitamin D deficiency results in an increased incidence of autoimmune disease. The authors discuss the accumulating evidence pointing to a link between vitamin D and autoimmunity. The optimal level of vitamin D intake is necessary to normalize the immune functions and it plays an important role in the development of self-tolerance. Targets for vitamin D in the immune system have been identified and the mechanism of vitamin D mediated immunoregulation is beginning to be understood. On the basic of recent knowledge, vitamin D causes a decrease in Th1-driven autoimmune response and repairs the function of regulatory T cells. Increased vitamin D intakes might decrease the incidence and severity of autoimmune diseases.]

Ca&Bone

[Modelling of burden of femoral neck fracture from purchaser’s point of view]

SEBESTYÉN Andor, PÉNTEK Márta, GULÁCSI László, NYÁRÁDY József

[OBJECTIVE - This study provides a model of the treatment cost of femoral neck fracture and financial burden of the annual fracture cases at 2009 financial level from health insurance point of view. METHOD - The costs of the treatment of femoral neck fractures are modelled according to the actually OEP reimbursed types of care including acute inpatient care, chronic inpatient care, outpatient care, pharmaceuticals and medical devices, home care (nursing), cost of travelling or transport and the disability to work. Cases healing following primary treatment (without complications) and cases with complications are examined separately. The costs of most common complications with large surgical operation are calculated. RESULTS - The cost of patients in active age-groups cured by primary treatment can vary in a range of 1.010.110- 1.479.034 HUF depending on cost level of individual care and utilization, while the cost of patients in retired agegroups (pensioners) can vary in a range 635.350- 1.104.274 HUF. The cost of patients with complication (primary treatment and complication) in active agegroups can reach. 1 858.438-3.133.096 HUF depending on cost level of individual care and utilization, while the cost of patients in retired age-groups (pensioners) can reach 1.108.918-2.383.576 HUF. According to our model calculations, the cost of primary treatment of femoral neck fractures and essential further treatment represents an annual burden of 4.373.857.668-6.247.717.438 HUF for the health insurance system. CONCLUSION - In order to reduce the incidence of hip fractures one should emphasize the importance of current and future interventions, which projects the possibility of reducing the financial burden at societal level. The analysis of financial burden could serve as a base for health-economics studies, by elaborating a cost-effective strategy supported by professional and political decision makers.]

Ca&Bone

[Forthcoming Congresses]

All articles in the issue

Related contents

Ca&Bone

[Management of hip fractures: practice, results, and problems in the last decade]

KRICSFALUSY Mihály, FLÓRIS István, CSERHÁTI Péter

[Among fractures attributable to osteoporosis, hip fractures are associated with the most severe consequences and the greatest costs. Surgical therapy for this condition is continuing to improve. Increasingly recent implants and techniques are being developed and introduced to successfully control postoperative adverse events. The authors briefly outline actual practice in Hungary and present some results of the follow-up of their patients in the last decade. These show that, in order to improve outcomes of hip fracture patients, all domains of management need to be addressed.]

Lege Artis Medicinae

[Resistant hypertension - differential diagnosis and therapy]

TISLÉR András

[Hypertension is considered resistant to therapy if the target blood pressure is not achieved despite treatment with three different types of antihypertensive drugs, including a diuretic. Causes of therapy resistance may be grouped into three broad categories: Pseudoresistance can be the result of inadequate blood pressure measurement technique, the “white-coat” effect or the patients’ noncompliance with pharmacological and nonpharmacological medical advices. Evaluation of the measurement technique - including the size of the cuff used - and blood pressure monitoring at home can help identify the causes of pseudoresistance. Secondary resistance comprises drug interactions and concomitant medical conditions that elevate blood pressure or antagonize antihypertensive therapy. In addition, secondary resistance can result from disorders associated with secondary hypertension, among which appropriate screening for hyperaldosteronism as well as for renoparenchymal and renovascular hypertension need special emphasis. Suboptimal therapy is frequently related to subclinical volume overload and the use of inappropriate type or dosing of diuretics. Furthermore, when choosing the optimal drug combination, care should be taken to inhibit the various systems that regulate blood pressure as much as possible. In addition to combining the most frequently used antihypertensive drugs, the use of aldosterone antagonists, vasodilators, nitrates or drugs affecting the central nervous system might help to optimise treatment.]

LAM Extra for General Practicioners

[RESISTANT HYPERTENSION - DIFFERENTIAL DIAGNOSIS AND THERAPY]

TISLÉR András

[Hypertension is considered resistant to therapy if the target blood pressure is not achieved despite treatment with three different types of antihypertensive drugs, including a diuretic. Causes of therapy resistance may be grouped into three broad categories: Pseudoresistance can be the result of inadequate blood pressure measurement technique, the “white-coat” effect or the patients’ noncompliance with pharmacological and nonpharmacological medical advices. Evaluation of the measurement technique - including the size of the cuff used - and blood pressure monitoring at home can help identify the causes of pseudoresistance. Secondary resistance comprises drug interactions and concomitant medical conditions that elevate blood pressure or antagonize antihypertensive therapy. In addition, secondary resistance can result from disorders associated with secondary hypertension, among which appropriate screening for hyperaldosteronism as well as for renoparenchymal and renovascular hypertension need special emphasis. Suboptimal therapy is frequently related to subclinical volume overload and the use of inappropriate type or dosing of diuretics. Furthermore, when choosing the optimal drug combination, care should be taken to inhibit the various systems that regulate blood pressure as much as possible. In addition to combining the most frequently used antihypertensive drugs, the use of aldosterone antagonists, vasodilators, nitrates or drugs affecting the central nervous system might help to optimise treatment.]

Lege Artis Medicinae

[Amlodipine/atorvastatin fix combination in general practice]

ÁBRAHÁM Erzsébet Judit

[In total 50 patients with hypertension and dyslipidaemia received combined antihypertensive and antilipid treatment. The main component of therapy was a fixed combination of amlodipine/ atorvastatin in different dose variations. The goal of the observation was to achieve optimal target blood pressure and lipid profile. During the six- month therapy, the baseline average blood pressure value was 161/90 mmHg and it decreased to 133/84 mmHg. The lipid profile also changed successfully. The average value of total cholesterol decreased from 5.9 mmol/l to 4.76 mmol/l. Over the six month period, amlodipine/ ator vastatin usage not only decreased the number of the heart and vascular system events, but increased the patients medicine compliance and therapy loyalty.]